HER2 mRNA status contributes to the discrepancy between gene amplification and protein overexpression in gastric cancer.

about

HER2 mRNA status contributes to the discrepancy between gene amplification and protein overexpression in gastric cancer.

Item

http://www.wikidata.org/entity/Q39067548

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

HER2 mRNA status contributes t ...... rexpression in gastric cancer.

@en

HER2 mRNA status contributes t ...... rexpression in gastric cancer.

@nl

type

Item

label

HER2 mRNA status contributes t ...... rexpression in gastric cancer.

@en

HER2 mRNA status contributes t ...... rexpression in gastric cancer.

@nl

prefLabel

HER2 mRNA status contributes t ...... rexpression in gastric cancer.

@en

HER2 mRNA status contributes t ...... rexpression in gastric cancer.

@nl

P1476

HER2 mRNA status contributes t ...... rexpression in gastric cancer.

@en

P2093

Gui-Fen Ma

http://www.w3.org/2001/XMLSchema#string

Hong Gao

http://www.w3.org/2001/XMLSchema#string

Qing Miao

http://www.w3.org/2001/XMLSchema#string

Shi-Yao Chen

http://www.w3.org/2001/XMLSchema#string

Tian-Cheng Luo

http://www.w3.org/2001/XMLSchema#string

Xiao-Qing Zeng

http://www.w3.org/2001/XMLSchema#string

Yi-Mei Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81

Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast cancer cells

New functions for the matrix metalloproteinases in cancer progression

Systematic review of HER2 breast cancer testing.

Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells.

How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?

Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Transforming growth factor-β1 and -β2 in gastric precancer and cancer and roles in tumor-cell interactions with peripheral blood mononuclear cells in vitro

P2888

s10620-013-2925-1

P304

328-335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10620-013-2925-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258253817

http://www.w3.org/2001/XMLSchema#string

P698

24185685

http://www.w3.org/2001/XMLSchema#string

P921

overexpression